Government work isn’t what it used to be.
There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.
Backlog of work grows at NIH as staff members are being hounded to quit
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
Appearing on the Cancer History Project Podcast, Michael P. Link, the Lydia J. Lee Professor in Pediatric Oncology at Stanford University, discussed his career in pediatric oncology, his 2011-2012 ASCO presidential term, and voiced concerns about what he’s seeing in oncology today.
In a press conference on Sept. 22, President Donald Trump, flanked by NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, HHS Secretary Robert Kennedy Jr., and CMS Administrator Mehmet Oz, touted that Tylenol use while pregnant is “probably” the cause of autism.
NIH’s new “unified grant funding policy,” is “not political,” NIH Director Jay Bhattacharya said during his remarks at Research!America’s annual National Health Research Forum Sept. 17.
Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.
With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.
